The purpose of this study is to evaluate the long term safety and tolerability of Liposomal
Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic
infection due to pseudomonas aeruginosa. This long-term, open-label, multi-cycle extension
study enrolled subjects who had successfully completed study TR02-108, were compliant with
the study protocol, and did not meet any of the listed study discontinuation criteria. The
safety and tolerability of LAI were evaluated for up to approximately 2 years.